Preferred Label : Tadalafil;

MeSH definition : A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.;

MeSH synonym : Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-;

MeSH hyponym : cialis; IC351; IC-351; IC 351; 351, IC;

MeSH CAS label : Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-;

MeSH Related Number : 171596-29-5;

Wikipedia link : https://en.wikipedia.org/wiki/Tadalafil;

Is substance : O;

UNII : 742SXX0ICT;

Details


Main resources

You can consult :

A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.

https://www.ema.europa.eu/en/medicines/human/EPAR/yuvanci
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
drug combinations
macitentan
macitentan
macitentan and tadalafil
Tadalafil
Tadalafil
drug approval
europe
adult
hypertension, pulmonary
Endothelin A Receptor Antagonists
Endothelin B Receptor Antagonists
phosphodiesterase 5 inhibitors
administration, oral
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3421137/fr/tadalafil-zentiva-tadalafil-dysfonction-erectile
2023
false
false
false
France
drugs, generic
evaluation of the transparency committee
erectile dysfunction
Tadalafil

---
https://www.has-sante.fr/jcms/p_3445464/fr/tadalafil-zentiva-tadalafil-dysfonction-erectile
2023
false
false
false
France
evaluation of the transparency committee
functional disorder, nos
Tadalafil
erectile dysfunction

---
https://www.has-sante.fr/jcms/p_3339979/fr/tadalafil-mylan-tadalafil-troubles-de-l-erection-lies-a-des-pathologies
2022
France
evaluation of the transparency committee
disease
priapism
registries
Pathology
Erection disorders
Disorders
Pathology
Tadalafil
erectile dysfunction
Pathology
Pathology
Pathology
Pathology
Pathology

---
https://www.has-sante.fr/jcms/p_3385976/fr/tadalafil-biogaran-tadalafil
2022
false
false
false
France
evaluation of the transparency committee
generations
Set, Psychology
device, nos
family characteristics
devices
Tadalafil

---
https://www.has-sante.fr/jcms/p_3189047/fr/kronalis
2020
false
false
false
France
Tadalafil
tadalafil
administration, oral
phosphodiesterase 5 inhibitors
evaluation of the transparency committee

---
https://www.has-sante.fr/portail/jcms/c_2863549/fr/tadalafil-quiver
2018
false
false
false
France
French
evaluation of the transparency committee
Tadalafil

---
https://www.has-sante.fr/portail/jcms/c_2801980/fr/talmanco
2017
false
France
French
Tadalafil
drugs, generic
Product containing precisely tadalafil 20 milligram/1 each conventional release oral tablet (clinical drug)
adult
evaluation of the transparency committee
insurance, health, reimbursement
idiopathic pulmonary arterial hypertension
Pulmonary arterial hypertension associated with connective tissue disease (disorder)
treatment outcome
administration, oral
hypertension, pulmonary
phosphodiesterase 5 inhibitors
Familial Primary Pulmonary Hypertension

---
Talmanco (previously Tadalafil Generics) - tadalafil
https://www.ema.europa.eu/medicines/human/EPAR/talmanco-previously-tadalafil-generics
2017
false
United Kingdom
English
French
syndication feed
Tadalafil
Tadalafil
drugs, generic
Product containing precisely tadalafil 20 milligram/1 each conventional release oral tablet (clinical drug)
europe
adult
pregnancy
breast feeding
drug approval
treatment outcome
administration, oral
drug interactions
risk assessment
drug evaluation, preclinical
hypertension, pulmonary
phosphodiesterase 5 inhibitors
phosphodiesterase 5 inhibitors
package leaflet
summary of product characteristics
drug evaluation

---
https://www.ema.europa.eu/medicines/human/EPAR/Tadalafil-Lilly
2017
false
United Kingdom
English
French
syndication feed
Tadalafil
Tadalafil
benign prostatic hyperplasia
Product containing tadalafil (medicinal product)
Product containing precisely tadalafil 2.5 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely tadalafil 5 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely tadalafil 10 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely tadalafil 20 milligram/1 each conventional release oral tablet (clinical drug)
treatment outcome
drug evaluation
administration, oral
cyclic nucleotide phosphodiesterases, type 5
erectile dysfunction
drug approval
drug interactions
drug evaluation, preclinical
tadalafil
phosphodiesterase 5 inhibitors
phosphodiesterase 5 inhibitors
package leaflet
summary of product characteristics
drug evaluation
prostatic hyperplasia

---
https://www.ema.europa.eu/medicines/human/EPAR/Tadalafil-Mylan
2015
false
United Kingdom
English
French
drugs, generic
syndication feed
Tadalafil
Tadalafil
treatment outcome
drug evaluation
tablets
administration, oral
cyclic nucleotide phosphodiesterases, type 5
erectile dysfunction
drug labeling
drug approval
drug interactions
drug evaluation, preclinical
tadalafil
phosphodiesterase 5 inhibitors
phosphodiesterase 5 inhibitors
package leaflet
summary of product characteristics
drug evaluation

---
https://www.ema.europa.eu/medicines/human/EPAR/Cialis
2012
false
United Kingdom
English
French
syndication feed
Tadalafil
Tadalafil
treatment outcome
drug evaluation
tablets
administration, oral
cyclic nucleotide phosphodiesterases, type 5
erectile dysfunction
drug labeling
drug approval
drug interactions
drug evaluation, preclinical
tadalafil
phosphodiesterase 5 inhibitors
phosphodiesterase 5 inhibitors
package leaflet
summary of product characteristics
drug evaluation

---
https://www.ema.europa.eu/medicines/human/EPAR/adcirca-previously-tadalafil-lilly
2012
false
United Kingdom
English
French
syndication feed
Tadalafil
Tadalafil
drug approval
treatment outcome
drug labeling
tablets
administration, oral
drug interactions
risk assessment
drug evaluation, preclinical
hypertension, pulmonary
phosphodiesterase 5 inhibitors
phosphodiesterase 5 inhibitors
package leaflet
summary of product characteristics
drug evaluation

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-05/synthese_davis_reevaluation_htap_2011-05-12_12-18-35_386.pdf
http://www.has-sante.fr/portail/jcms/c_1053751/medicaments-de-lhypertension-arterielle-pulmonaire-idiopathique-ou-associee-a-une-connectivite
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
Sildenafil Citrate
Tadalafil
hypertension, pulmonary
collagen diseases
epoprostenol
antihypertensive agents
sulfonamides
treprostinil
epoprostenol
phosphodiesterase 5 inhibitors
iloprost
receptors, endothelin
ambrisentan
phenylpropionates
DERMATITIS
survival analysis
Antihypertensives for pulmonary arterial hypertension
treatment outcome
pyridazines
Bosentan

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Adcirca_July-19-2010_f.pdf
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Adcirca_July-19-2010_f.pdf
2010
false
Canada
French
Tadalafil
Tadalafil
drug evaluation
hypertension, pulmonary
administration, oral
treatment outcome
Cost-Benefit analysis
phosphodiesterase 5 inhibitors

---
http://www.has-sante.fr/portail/jcms/c_973815/adcirca
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-08/adcirca_-_ct-7800.pdf
2010
false
France
French
Tadalafil
Tadalafil
hypertension, pulmonary
treatment outcome
adult
administration, oral
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_996989/adcirca-tadalafil-inhibiteur-de-la-phosphodiesterase-5
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-08/adcirca_-_ct-7800.pdf
2010
false
France
French
Tadalafil
Tadalafil
administration, oral
hypertension, pulmonary
treatment outcome
adult
phosphodiesterase 5 inhibitors
guidelines for drug use
evaluation of the transparency committee

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=68937321
2008
false
France
French
Tadalafil
tablets
administration, oral
tadalafil
drug information

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69226514
2008
false
France
French
Tadalafil
tablets
administration, oral
tadalafil
drug information

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65834394
2008
false
France
French
Tadalafil
tablets
administration, oral
tadalafil
drug information

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65958239
2008
false
France
French
Tadalafil
tablets
administration, oral
tadalafil
drug information

---
http://www.has-sante.fr/portail/display.jsp?id=c_400185
2005
false
France
French
Tadalafil
erectile dysfunction
treatment outcome
phosphodiesterase 5 inhibitors
tadalafil
evaluation of the transparency committee

---
Nous contacter.
05/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.